USNA - NYSE
USANA Health Sciences, Inc.
$17.46
-3.3%USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
At a Glance
Live SnapshotUSANA Health Sciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
USANA Health Sciences, Inc. Income Statement
USNA • NYSE
| USANA Health Sciences, Inc. Income Statement | Jan 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
925.3M | 854.5M | 921M | 998.6M | 1.2B | 1.1B | 1.1B | 1.2B | 1B | 1B | 918.5M | 790.5M | 718.2M | 648.7M | 581.9M | 517.6M | 436.9M | 429M | 423.1M | 374.2M | |
GROSS PROFIT | ||||||||||||||||||||
(200.9M) | (175.8M) | (189.4M) | (207.3M) | (230.9M) | (222.9M) | (187.5M) | (200.7M) | (179.4M) | (180.2M) | (159.7M) | (140.8M) | (127.4M) | (115.8M) | (101.7M) | (95.5M) | (89.8M) | (88.9M) | (87.9M) | (89.5M) | |
724.4M | 678.8M | 731.6M | 791.3M | 955.5M | 911.8M | 873.4M | 988.5M | 867.9M | 825.9M | 758.8M | 649.7M | 590.7M | 532.9M | 480.2M | 422.2M | 347.1M | 340.1M | 335.3M | 284.6M | |
OPERATING INCOME | ||||||||||||||||||||
(673.5M) | (612.4M) | (638.5M) | (683.7M) | (785.3M) | (735.3M) | (727.2M) | (800.2M) | (735.4M) | (687.3M) | (617.2M) | (533.6M) | (474M) | (434.7M) | (403M) | (353.9M) | (296.3M) | (292.1M) | (264.6M) | (222.3M) | |
(337.4M) | (600.9M) | (627.1M) | (672.1M) | (774.2M) | (724.7M) | (727.2M) | (800.2M) | (735.4M) | (687.3M) | (617.2M) | (533.6M) | (474M) | (434.7M) | (403M) | (353.9M) | (296.3M) | (292.1M) | (261.2M) | (219.1M) | |
(0.0) | (11.6M) | (11.4M) | (11.6M) | (11.1M) | (10.6M) | (10.3M) | (10.2M) | (9M) | (8.8M) | (6.4M) | (5.1M) | (5.1M) | (4.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (3.4M) | (3.2M) | |
50.9M | 66.3M | 93.1M | 107.6M | 170.2M | 176.5M | 146.2M | 188.4M | 132.5M | 138.6M | 141.7M | 116.1M | 116.7M | 98.2M | 77.3M | 68.2M | 50.8M | 48M | 70.7M | 62.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(842K) | (281K) | (262K) | (192K) | (57K) | (507K) | (66K) | (36K) | (46K) | (444K) | (15K) | (129K) | (1K) | (20K) | (9K) | (94K) | (609K) | (792K) | (0.0) | (0.0) | |
1.6M | 11M | 9.4M | 3.6M | 2.5M | 2M | 4.6M | 4.4M | 2.1M | 1M | 1.1M | 371K | 463K | 227K | 182K | 73K | -527K | -543K | 0.0 | 0.0 | |
(336.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -10.3M | (3.2M) | (2.1M) | -70K | (927K) | -449K | -131K | (247K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-9.3M | 10M | 9.4M | 1M | 450K | 1.5M | 4.3M | 3.2M | 2.1M | -70K | 927K | -449K | -131K | 247K | 222K | 648K | 187K | -1.7M | 471K | 1.4M | |
41.5M | 76.4M | 102.5M | 108.6M | 170.6M | 177.9M | 150.5M | 191.5M | 134.6M | 138.6M | 142.6M | 115.7M | 116.6M | 98.4M | 77.5M | 68.9M | 51M | 46.3M | 71.2M | 63.8M | |
NET INCOME | ||||||||||||||||||||
(30.1M) | (34.3M) | (38.7M) | (39.3M) | (54.1M) | (53.3M) | (50M) | (65.3M) | (72.1M) | (38.5M) | (47.9M) | (39M) | (37.6M) | (32M) | (26.7M) | (23.2M) | (17.4M) | (16.4M) | (25.2M) | (22.5M) | |
10.8M | 42M | 63.8M | 69.4M | 116.5M | 124.7M | 100.5M | 126.2M | 62.5M | 100M | 94.7M | 76.6M | 79M | 66.4M | 50.8M | 45.7M | 33.6M | 29.9M | 45.3M | 41.3M |
SEC Filings
USNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q2 Q2 | May 12, 2026 | April 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | January 03, 2026 | 2026 | |
10-K 10-K 2026 FY FY | March 16, 2026 | January 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 18, 2026 | February 17, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | February 11, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 27, 2025 | 2025 |
Related Guides
Continue your USNA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.